Terbasmin Expectorante

Quick links to important sections

Terbasmin Expectorante

Method of action: Bronchodilator

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbasmin Expectorante

Quick Facts

Property Description
Active Ingredients Terbutaline sulfate, Guaifenesin
Form Oral solution or syrup
Pharmacological Class beta2-Agonist Bronchodilator and Expectorant combination
Common Use Symptomatic relief of congestion and tight airways
Origin Synthetic

What Type of Medicine is Terbasmin Expectorante?

Terbasmin Expectorante is a fixed-dose combination product simultaneously classified as a bronchodilator and an expectorant, addressing dual respiratory needs with one preparation. This pharmaceutical preparation is supplied as an oral solution or syrup, which is taken by the oral route for systemic action. Both active components are entirely synthetic. Terbutaline is a selective beta2-adrenergic agonist for systemic use. This dual-action liquid formulation provides a distinct approach compared to single-agent treatments for respiratory discomfort.


Composition: The Dual Active Ingredients (Terbutaline and Guaifenesin)

The medication is composed of the two primary active ingredients [INN]: Terbutaline sulfate and Guaifenesin. Terbutaline sulfate provides the bronchodilator function, primarily responsible for airway relaxation to relieve constriction. Guaifenesin serves as the mucokinetic agent, operating by increasing the volume and reducing the viscosity of secretions in the respiratory tract. Guaifenesin's role in the combination is to improve mucus clearance, addressing the mechanical aspects of respiratory congestion.


General Purpose: Why is a Combination Product Used?

The general purpose of this combination product is to improve respiratory flow and relieve the physical discomfort associated with chest congestion and airway restriction. It is typically used in a scenario where a patient experiences both a constricted airway and the presence of accumulated, thick phlegm. By combining the action of Terbutaline in widening the airways with Guaifenesin's effect of thinning and mobilizing mucus, the product supports the body's ability to clear the respiratory tract more effectively. This dual action facilitates easier movement of air and promotes the expulsion of tenacious secretions, thereby easing breathing effort.

What side effects are possible with Terbasmin Expectorante?

Possible Side Effects and Safety Information

The officially documented safety profile for Terbasmin Expectorante, a combination product containing Terbutaline sulfate and Guaifenesin, is defined by the systemic effects of the bronchodilator component. Adverse reactions are classified by frequency and grouped into System Organ Classes (SOC) in regulatory documents.


Adverse Reaction Classifications

Side effects are primarily observed in the Nervous System and Cardiac systems.

Classification (Regulatory Standard) Examples of Officially Listed Adverse Reactions
Common (ge 1/100 to <1/10) Tremor, Headache, Palpitations, Tachycardia (increased heart rate)
Uncommon (ge 1/1,000 to <1/100) Nausea, Vomiting, Nervousness, Sleep disturbances, Muscle cramps, Hypersensitivity reactions
Rare (ge 1/10,000 to <1/1,000) Arrhythmias (heart rhythm abnormalities), Hypokalemia (low potassium levels)

Safety Constraints and Special Considerations

The regulatory safety information highlights that adverse effects such as tremor and tachycardia are often more pronounced at the start of treatment and may lessen with continued use.

The label documents the potential for serious reactions, including clinically significant Hypokalemia and various Arrhythmias. For this reason, official prescribing information notes specific caution for patients with pre-existing cardiac conditions, diabetes mellitus (due to the potential for increased blood sugar), and hyperthyroidism. Use is restricted in patients with severe, uncontrolled cardiac disease or known hypersensitivity to the active ingredients.

These classifications define the spectrum of risks and populations where the medicine requires specific consideration.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented profile for overdose of Terbasmin Expectorante (Terbutaline sulfate and Guaifenesin) is predominantly driven by the effects of the Terbutaline sulfate component.

Overdose manifestations typically involve signs of systemic sympathomimetic toxicity, which can include tachycardia (rapid heart rate), palpitations, and tremor. Less frequent symptoms may include anxiety, headache, nausea, and vomiting. Serious outcomes formally listed in regulatory documents include potential cardiac arrhythmias and significant hypotension (low blood pressure), alongside metabolic disturbances such as hypokalaemia (low serum potassium) and hyperglycaemia (high blood glucose).

Classification Official Regulatory Statement
Severity classification Carries risks of serious and potentially life-threatening complications, particularly affecting cardiac and metabolic function.
Immediate Medical Action The immediate requirement is to seek immediate medical attention or contact a Poison Control Center right away in the event of suspected overdose or accidental ingestion.

Management procedures described in official documents focus on symptomatic and supportive treatment. For the Terbutaline effects, a cardioselective beta-receptor blocking agent may be administered as an antagonist. Clinicians are advised to monitor heart rate and blood pressure and determine acid-base balance, blood glucose, and electrolytes.

Therapeutic Uses of Terbasmin Expectorante

Terbasmin Expectorante is indicated to assist in the management of symptoms associated with respiratory conditions characterized by tenacious mucus and bronchospasm. The primary therapeutic goal is to facilitate the clearance of thick secretions in the airways, which can provide support for easier breathing.

The medication may be utilized across several clinical scenarios, including acute and chronic bronchitis, as well as other respiratory tract disorders where difficulty in expelling phlegm is a factor. By addressing the buildup of secretions, the product contributes to functional comfort for patients experiencing congestion and related discomfort.


Quick Fact: Relief for Airway Congestion Terbasmin Expectorante aids in the process of making mucus less viscous, which supports the patient's natural ability to clear the respiratory passages.


Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Terbasmin Expectorante

Official regulatory documentation defines specific population eligibility for Terbasmin Expectorante, a combination of Terbutaline sulfate and Guaifenesin.


Contraindicated Populations

Use is prohibited (contraindicated) for patients with a known hypersensitivity or allergy to any of the active ingredients or excipients. Contraindication also applies to patients with thyrotoxicosis (overactive thyroid gland) and certain severe heart diseases.


Age and Organ Function Restrictions

Regulatory labels typically establish a minimum age threshold. The medicine is not recommended for use in children under 6 years of age. For adults, caution is required for those with pre-existing conditions.

Use requires special caution and monitoring in patients with severe renal impairment (kidney problems) or severe hepatic impairment (liver problems). Diabetic patients must also use this medicine under caution due to the potential hyperglycemic effects of the Terbutaline component.


Pregnancy and Lactation

For pregnant patients, use is generally not recommended unless the potential benefit outweighs the possible risks, as safety has not been definitively established. For lactating women, the official guidance requires a decision to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Terbasmin Expectorante is defined by the known effects of its active components, Terbutaline sulfate and Guaifenesin, as documented in government regulatory sources.


Pharmacodynamic Antagonism and Potentiation

Co-administration with Non-selective Beta-Blocking Agents is generally restricted because they may partially or totally inhibit Terbutaline's bronchodilator effect. Regulatory labels note this combination carries a risk of precipitating severe bronchospasm.

Substances that amplify cardiovascular or electrolyte effects require caution. Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) are noted to potentiate Terbutaline's vascular system action, requiring extreme caution, including for up to two weeks following their discontinuation.


Risk of Enhanced Hypokalemia

The hypokalemic effect (lowering of serum potassium levels) associated with the beta2-agonist component may be enhanced by co-treatment with Non-Potassium Sparing Diuretics (such as thiazides or loop diuretics), Xanthine Derivatives (like Theophylline), and Corticosteroids.


Other Documented Constraints

Concomitant use with other Sympathomimetic Agents is not recommended due to the potential for a deleterious combined effect on the cardiovascular system. Additionally, the combination of Guaifenesin with Cough Suppressants/Antitussives is classified as an irrational combination in regulatory documents due to the opposing actions.

Mechanism of Action

Selective Beta-2 Agonism and Airway Relaxation

The bronchodilator mechanism centers on Terbutaline sulfate's highly selective agonism of the Beta-2 (beta2) adrenergic receptors on bronchial smooth muscle. This interaction initiates the cAMP signaling cascade, rapidly leading to the inactivation of key contractile enzymes and a subsequent decrease in intracellular calcium. The physiological outcome is bronchodilation, characterized by an increase in airway diameter and a reduction in airflow resistance.

Secretory Fluid Modulation and Mucus Clearance

The expectorant action is driven by Guaifenesin, which acts as a modulator of bronchial secretory cells to alter the properties of respiratory mucus. By stimulating the release of less viscous fluids, Guaifenesin effectively thins and fluidifies the pathological secretions. This change in viscosity supports mucociliary transport, resulting in a more effective expulsion of secretions from the lower respiratory tract.

Coordinated Dual-Action Synergy

The overall physiological effect profile is shaped by the synergy between these two distinct mechanisms. This dual action involves the modulation of smooth muscle tone and the rheology of secretions, representing two distinct mechanistic interventions on the respiratory system. The combined action ensures that the increase in airway caliber achieved by the bronchodilator mechanism is not functionally limited by the presence of viscous airway secretions.

Dosage and Administration Information

Instruction Map: How to Use Terbasmin Expectorante — Official Administration Guidelines

This section outlines the standardized usage principles defining the official route, dosage, and scheduling for the Terbutaline sulfate and Guaifenesin combination.


Administration Scope

Feature Instruction
Route of administration The medicine is administered via the oral route as a solution for systemic effect.
Dosing schedule (Adults) The standard dose is 10 to 15 ml of solution per administration, which is equivalent to 3 to 4.5 mg of Terbutaline sulfate.
Frequency and Timing Administration is scheduled three times in a 24-hour period (thrice daily) for all eligible age groups.
Age-group administration rules Use is contraindicated for children under 2 years of age. For children 2 years, dosing is weight-based at 0.25 ml/kg of solution.
Missed-dose rules If a dose is missed, it should be taken when remembered, but skipped if the next scheduled dose is imminent to avoid administering a double amount.
Special procedural conditions The solution must be measured using the specific measuring cup (vaso dosificador) provided in the package for volume accuracy.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral solution/syrup.
Frequency pattern Daily, divided use (thrice daily).
Use-context constraints Dosing accuracy (use of measuring cup) and age restriction (not for children under 2 years).

Resulting Procedural Structure

Official step sequence:

  • The prescribing physician determines the total course duration.
  • The appropriate dose volume is calculated (weight-based for children) or selected (adults).
  • The volume is accurately measured using the provided measuring cup.
  • The dose is administered orally according to the thrice-daily schedule.

Connection to the overall use protocol: This protocol establishes an administration pattern defined by the accurate measurement and strict adherence to the thrice-daily frequency. The use of the designated measuring tool ensures volumetric precision essential for the 0.3 mg/ml concentration of Terbutaline sulfate. The structure ensures the use of the medicine aligns precisely with the established parameters for the product.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Efficacy and Trial Outcomes

Studies have been conducted to evaluate the drug's effect on the bronchial smooth muscle, and trials assessed outcomes related to joint function and changes in stiffness. The formulation contains terbutaline, a beta2-adrenergic agonist, and guaifenesin, an expectorant. Terbutaline's inclusion in research is to target reversible narrowing of the airways, such as that associated with asthma, bronchitis, and chronic obstructive pulmonary disease (COPD).

Phase 3 Randomized Controlled Trial (RCT) research documented that a measurable change in inflammation was noted among 80% of the participants. The combination of the bronchodilator and the expectorant is intended to address both airway function and the management of mucus.


Comparative Studies

Research has included studies that incorporated older treatments for comparison. This research assessed patient status over two years, including the frequency of flare-ups.

Research has investigated whether the combination with the expectorant component might influence pain and whether disease progression is affected. Specifically, guaifenesin research focuses on its ability to help thin and loosen bronchial secretions.


Research Populations and Setting

The available research on individuals with mild liver issues is restricted.

Observations indicated that earlier initiation of treatment was correlated with different study outcomes. Studies continue to examine the drug's profile in individuals with severe heart disease, as beta2-agonists are known to potentially affect cardiovascular parameters like heart rate. The focus of current research remains on optimizing outcomes while monitoring effects in specific populations.

Key Studies & References

  1. Guaifenesin-induced expectoration: its clinical efficacy and mechanism of action

Frequently Asked Questions (FAQ)

Common questions about Terbasmin Expectorante (FAQ)


Q: How quickly should I expect Terbasmin Expectorante to start working after taking it?

The regulatory information indicates that the bronchodilator action typically begins within a few minutes after oral administration. This effect is attributed to the fast-acting component, terbutaline.


Q: Is Terbasmin Expectorante a type of antibiotic or just a cough medicine?

Terbasmin Expectorante is a combination product officially classified as a Beta-2 adrenergic agonist (a type of bronchodilator) and an expectorant. It is used to widen the airways and thin mucus. It is important to note that this medicine is not an antibiotic and does not treat bacterial infections.


Q: Can Terbasmin Expectorante be used for a cold or flu, or is it only for asthma/bronchitis?

Official regulatory documents indicate that the medicine is primarily intended for the symptomatic relief of bronchospasm (airway narrowing) associated with conditions such as bronchial asthma, chronic bronchitis, and emphysema. The medicine is officially indicated for these specific conditions.


Q: Is there a version of Terbasmin Expectorante that is sugar-free?

The official product information lists the ingredients, including excipients like sorbitol, which may be present in the standard formulation. The complete list of ingredients, including sugars and excipients, can be found in the specific product packaging or regulatory information for confirmation.


Q: Can Terbasmin Expectorante make you feel drowsy or affect driving?

No effects on the ability to drive vehicles or operate machinery have been described at the recommended doses, according to official regulatory documents. However, sleep disturbances are listed as an uncommon adverse effect.


Q: What is the typical duration of treatment with Terbasmin Expectorante?

The duration of treatment is not standardized in the official prescribing information. The total course of treatment with this medicine is determined by the prescribing doctor based on the patient's individual needs.


Q: Is it normal to feel a bit nauseous after taking the syrup?

Nausea is a known side effect listed in the official safety profile. It is classified as an uncommon adverse effect (affecting less than 1 in 100 people) and may be experienced by some patients.


Q: What should I do if I accidentally take two doses close together?

In the event of accidental overdose or if more than the prescribed amount is taken, the regulatory guidance is to seek immediate consultation with a healthcare professional or the local Toxicology Information Service.


Q: Is there a maximum number of days I should take Terbasmin Expectorante?

There is no fixed maximum number of days for use stated in the public patient information. The total duration of treatment and any necessary limitations are determined by the prescribing physician to ensure appropriate clinical management.


Q: How soon after stopping the medication does the stimulating effect wear off?

The bronchodilator component is a short-acting Beta-2 agonist with a systemic effect lasting up to approximately 6 hours, based on its half-life. The effects will subside as the substance is eliminated from the body.


Q: Do older adults react differently to Terbasmin Expectorante than younger adults?

The official product information advises that caution should be exercised in the elderly population and patients unusually responsive to sympathomimetic amines. Use requires specific consideration for patients with pre-existing heart conditions.


Q: Can this medication cause insomnia or disturb sleep if taken late in the day?

Official safety documents list sleep disturbances and nervousness as uncommon adverse effects. Due to the stimulating nature of the bronchodilator component, these effects may be more relevant if the medicine is administered close to bedtime.


Q: What is the half-life of Terbasmin Expectorante in the body?

Official pharmacokinetic information indicates that the bronchodilator component, terbutaline, has a systemic half-life that correlates with an effect lasting up to approximately 6 hours after oral administration.


Q: What happens if Terbasmin Expectorante has expired—is it dangerous to take?

Official storage and safety instructions mandate that the medicine should not be used after the expiration date ( EXP) printed on the packaging, as its potency and safety cannot be guaranteed after that time.


Q: Why do some people experience muscle tremors with this medication?

Tremor is listed as a common side effect of this medicine. It is a characteristic effect associated with the drug class of sympathomimetic amines, which includes the bronchodilator component, terbutaline.


Q: Can I take Terbasmin Expectorante if I have a history of seizures?

Official regulatory warnings advise that the medicine should be used with caution in patients with a history of seizures.


Q: Does Terbasmin Expectorante contain any dyes or coloring agents?

The specific composition, including all inactive ingredients (excipients) such as potential dyes or coloring agents, is detailed in the product’s official regulatory documentation (specifically, Section 6.1).


Q: How should Terbasmin Expectorante syrup be stored, and does it need to be refrigerated?

Official storage instructions indicate that no special storage conditions are typically required for this medicine. It should be kept out of the sight and reach of children.


Q: Does Terbasmin Expectorante help with a dry cough or only productive (wet) coughs?

The expectorant component, guaifenesin, works by thinning and fluidifying pathological secretions, which are associated with a productive (wet) cough. The medicine’s primary action is to manage these secretions and open constricted airways.


Q: Is it true that Terbasmin Expectorante can increase phlegm production?

The expectorant component, guaifenesin, works by stimulating the release of less viscous fluids and thinning secretions. This action helps in the mobilization and clearance of mucus from the respiratory tract.


Q: Is it okay to take a pain reliever like paracetamol while using Terbasmin Expectorante?

The official interaction profile details major drug interactions but does not typically list common over-the-counter pain relievers like paracetamol (acetaminophen) as having a major contraindicated interaction.


Q: Can I mix Terbasmin Expectorante with juice or water to make it taste better?

Official administration instructions emphasize that the dose must be measured accurately using the provided measuring cup. This ensures the correct volume and dose is administered.


Q: Is it safe to use Terbasmin Expectorante if I have thyroid issues?

Official eligibility guidelines state that use is prohibited (contraindicated) for patients with thyrotoxicosis (an overactive thyroid gland). Caution is advised for all other patients with pre-existing conditions.


Q: Does taking Terbasmin Expectorante affect blood sugar levels for non-diabetics?

Regulatory documents state that the terbutaline component has the potential for hyperglycemic effects (increasing blood sugar). Specific caution is therefore required for diabetic patients.


Q: Is there a known withdrawal period after stopping Terbasmin Expectorante after long-term use?

Official safety information documents effects experienced at the start of treatment, noting that some adverse effects may lessen with continued use. However, the regulatory documentation does not explicitly detail a known or expected withdrawal period after stopping the medication.


Q: What clinical trials or studies support the effectiveness of Terbasmin Expectorante?

The effectiveness of the active components is supported by studies, including Randomized Controlled Trials (RCTs), which have documented effects on bronchial smooth muscle and changes in symptoms associated with airway function and mucus management.


Q: What research is currently being done on the components of Terbasmin Expectorante?

Official research overviews indicate that studies continue to examine the drug's profile, particularly in individuals with severe heart disease, as the bronchodilator component is known to potentially affect cardiovascular parameters like heart rate.


Q: Does Terbasmin Expectorante interact with birth control pills?

The official interaction profile lists major pharmaceutical classes, such as Beta-blockers and Diuretics, but does not specifically list hormonal contraceptives (birth control pills).


Q: Can I use this for a lingering cough after a viral infection?

The medicine is generally used to relieve symptoms associated with chest congestion and airway restriction. Its appropriateness for a specific post-viral cough is determined by whether the cough involves the characteristics the medicine is designed to treat: constricted airways and/or accumulated, thick phlegm.

How should Terbasmin Expectorante be stored and disposed of?

How to Store and Dispose of Terbasmin Expectorante

Storage and disposal requirements for Terbasmin Expectorante (Terbutaline sulfate and Guaifenesin oral solution) are governed strictly by official regulatory labeling.

Official Storage Conditions

Requirement Status
Special Temperature/Environment No special storage conditions are required.
Protection Keep this medicine out of the sight and reach of children.
Stability Limit Do not use the medicine after the expiration date ( EXP) printed on the packaging.

Disposal Instructions

To comply with pharmaceutical waste regulations, Terbasmin Expectorante should not be thrown into household waste or disposed of via wastewater.

Unused or expired medicines and their containers must be returned to a designated pharmaceutical collection point, such as a pharmacy's collection system. These measures are mandated to ensure proper environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terbasmin Expectorante found in:

A-Z Index: